Region Halland

The research at Region Halland focuses on cardiovascular diseases such as atrial fibrillation, heart failure with preserved ejection fraction, and stroke prevention in patients with kidney impairment.

• Anticoagulation strategies to reduce stroke in chronic kidney disease patients with atrial fibrillation
• Evaluation of mineralocorticoid receptor antagonists to lower heart‑failure hospitalizations
• Pragmatic registry‑based trials assessing real‑world outcomes in heart failure with preserved ejection fraction

Ongoing studies aim to improve survival and quality of life for individuals with complex heart conditions, leveraging the hospital’s multidisciplinary expertise.

Trials at the Varberg clinic explore safe and effective methods for labour induction, comparing outpatient and inpatient settings to enhance maternal care.

• Outpatient labour induction safety and efficacy
• Patient‑centered protocols for managing pregnancy complications
• Impact of induction setting on maternal and neonatal outcomes

The research supports evidence‑based guidelines that aim to improve obstetric outcomes for women throughout the region.

The site conducts studies on multiple myeloma, focusing on innovative immunotherapies and strategies for treatment discontinuation.

• Bispecific antibody therapy and remission duration in multiple myeloma
• Minimal residual disease assessment after combination regimens
• Strategies for treatment‑free intervals following intensive therapy

Findings aim to extend survival while reducing treatment burden for patients with plasma‑cell malignancies.

Research includes investigations of new agents to preserve insulin secretion in type 1 diabetes and to slow chronic kidney disease progression.

• Ixekizumab effect on residual insulin production in newly diagnosed type 1 diabetes
• Combination of baxdrostat and dapagliflozin to protect kidney function
• Hormone‑modulating therapies targeting metabolic control

These trials seek to preserve organ function and improve long‑term outcomes for individuals with endocrine disorders.

Clinical work at the hospital targets neoplasms, evaluating cutting‑edge therapies and post‑transplant care for solid and blood cancers.

• Autologous stem‑cell transplantation protocols for transplant‑eligible myeloma patients
• Assessment of disease‑free survival after innovative drug combinations
• Integration of targeted agents into standard oncologic practice

By partnering with national cancer networks, the site contributes to advancing therapeutic options for Swedish patients.